Drugmaker Wyeth is reportedly in talks to acquire Crucell NV, a Dutch pharmaceutical of medicines to fight AIDS, rabies and Ebola, Bloomberg reports.

The purchase is valued at $1.35 billion, according to the report which quotes an anonymous person familiar with the deal.

A spokesman for Leiden, Netherlands-based Crucell confirmed the negotiations on Thursday but denied to talk about the amount involved.